Alpha Teknova (TKNO) Stock Price, News & Analysis

Company Overview

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Key Stats

• Today's Range: $7.64 to $8.14
• 50-Day Range: $7.24 to $9.76
• 52-Week Range: $1.15 to $10.37
• Volume: 127,032 shs
• Average Volume: 238,008 shs
• Market Capitalization: $407.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Alpha Teknova Stock Analysis - MarketRank™

Alpha Teknova scored higher than 19% of companies evaluated by MarketBeat, and ranked 879th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alpha Teknova has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Alpha Teknova has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alpha Teknova are expected to grow in the coming year, from ($0.58) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Teknova is -10.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Teknova is -10.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Teknova has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.93% of the float of Alpha Teknova has been sold short.

Short Interest Ratio / Days to Cover

Alpha Teknova has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Teknova has recently decreased by 3.07%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Teknova does not currently pay a dividend.

Dividend Growth

Alpha Teknova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.93% of the float of Alpha Teknova has been sold short.

Short Interest Ratio / Days to Cover

Alpha Teknova has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Teknova has recently decreased by 3.07%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.95

News Sentiment

Alpha Teknova has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Alpha Teknova this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for TKNO on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpha Teknova insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.20% of the stock of Alpha Teknova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.81% of the stock of Alpha Teknova is held by institutions.

TKNO Stock Analysis - Frequently Asked Questions

How have TKNO shares performed this year?

Alpha Teknova's stock was trading at $8.35 at the start of the year. Since then, TKNO stock has decreased by 7.1% and is now trading at $7.76.
View the best growth stocks for 2025 here.

How were Alpha Teknova's earnings last quarter?

Alpha Teknova, Inc. (NASDAQ:TKNO) announced its earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.04. The business had revenue of $9.58 million for the quarter, compared to analysts' expectations of $9.30 million. Alpha Teknova had a negative trailing twelve-month return on equity of 35.30% and a negative net margin of 87.17%.

When did Alpha Teknova IPO?

Alpha Teknova (TKNO) raised $90 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

Who are Alpha Teknova's major shareholders?

Top institutional investors of Alpha Teknova include Invesco Ltd. (2.07%), Balyasny Asset Management L.P. (1.88%), Conestoga Capital Advisors LLC (0.46%) and Bank of America Corp DE (0.42%). Insiders that own company stock include Telegraph Hill Partners Iv, L, Ted Davis, J Matthew Mackowski, Stephen Gunstream, Matthew Lowell, Damon Terrill, Lisa Hood and Ken Gelhaus.
View institutional ownership trends.

How do I buy shares of Alpha Teknova?

Shares of TKNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alpha Teknova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Teknova investors own include Myomo (MYO), Cassava Sciences (SAVA), Heron Therapeutics (HRTX), Taboola.com (TBLA), Ultralife (ULBI), NVIDIA (NVDA) and Sensus Healthcare (SRTS).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 3/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TKNO
• CUSIP: N/A
• CIK: 1850902
• Web: www.teknova.com
• Phone: 831-637-1100
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +6.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,780,000.00
• Net Margins: -87.17%
• Pretax Margin: -88.14%
• Return on Equity: -35.30%
• Return on Assets: -24.52%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 4.73
• Quick Ratio: 3.94

Sales & Book Value

• Annual Sales: $36.68 million
• Price / Sales: 11.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.21 per share
• Price / Book: 3.62

Miscellaneous

• Outstanding Shares: 53,310,000
• Free Float: 45,205,000
• Market Cap: $425.95 million
• Optionable: Not Optionable
• Beta: 0.34